Baseline characteristics of subjects in the study
| Glargine | NPH | |
|---|---|---|
| n | 367 | 389 |
| Sex (F/M) (%) | 45/55 | 44/56 |
| Age (years) | 55 ± 9.5 | 56 ± 8.9 |
| Duration of diabetes (years) | 8.4 ± 5.55 | 9.0 ± 5.57 |
| BMI (kg/m2) | 32.5 ± 4.64 | 32.2 ± 4.80 |
| FPG (mg/dl [mmol/l]) | 198 (11.0) ± 49 (2.71) | 194 (10.8) ± 47 (2.61) |
| HbA1c (%) | 8.61 ± 0.9 | 8.56 ± 0.9 |
| Ethnicity (%) | ||
| White | 84 | 83 |
| Black | 11 | 13 |
| Asian | 3 | 3 |
| Multiracial | 1 | 1 |
| Hispanic heritage (%) | 10 | 6 |
| Prior therapy (%) | ||
| SU + metformin | 71 | 74 |
| SU only | 11 | 10 |
| Metformin only | 8 | 7 |
| SU + TZD | 6 | 5 |
| Metformin + TZD | 3 | 3 |
| TZD only | <1 | <1 |
Data are means ± SD, unless otherwise noted. SU, sulfonylurea; TZD, thiazolidinedione.